(HLN) Haleon - Ratings and Ratios
Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US4055521003
HLN EPS (Earnings per Share)
HLN Revenue
HLN: Oral Health, Vitamins, Respiratory, Pain Relief, Digestive
Haleon plc is a global consumer healthcare company that develops, manufactures, and markets a diverse portfolio of products across various therapeutic categories, including oral health, vitamins and supplements, over-the-counter (OTC) medications, and pain relief products. The companys product portfolio is backed by a robust brand presence, with well-established names such as Sensodyne, Centrum, and Panadol, among others. With a history dating back to 1715, Haleon has evolved through strategic acquisitions and partnerships to become a leading player in the consumer healthcare industry.
The companys global footprint spans across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific, providing a diversified revenue stream. Haleons products cater to a wide range of consumer needs, from oral health and wellness to pain management and digestive health. The companys commitment to research and development enables it to stay competitive in a rapidly evolving market landscape.
Analyzing the technical data, Haleon plcs stock (HLN) is currently trading at $11.41, above its 20-day, 50-day, and 200-day simple moving averages (SMA20, SMA50, and SMA200) of $10.91, $10.38, and $9.93, respectively. This indicates a positive short-term trend. The Average True Range (ATR) of 0.19 represents a 1.65% volatility, which is relatively moderate. Given the current trend and volatility, a potential forecast is that HLN may continue its upward momentum, potentially reaching $12.50 in the near term, driven by its strong brand portfolio and diversified global presence.
From a fundamental perspective, Haleon plc has a market capitalization of $50.998 billion USD, with a price-to-earnings (P/E) ratio of 26.98 and a forward P/E of 22.08. The companys return on equity (RoE) stands at 8.71%. Considering these metrics, Haleon appears to be reasonably valued, with a moderate P/E ratio and a stable RoE. A forecast based on these fundamental data points suggests that Haleons stock may continue to perform steadily, driven by its robust product portfolio and global reach. Assuming a stable macroeconomic environment, HLNs stock price may reach $14.00 by the end of the year, representing a potential upside of around 23% from current levels.
Additional Sources for HLN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
HLN Stock Overview
Market Cap in USD | 48,876m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2022-07-22 |
HLN Stock Ratings
Growth Rating | 55.1 |
Fundamental | 53.5 |
Dividend Rating | 48.4 |
Rel. Strength | 40.6 |
Analysts | 4 of 5 |
Fair Price Momentum | 10.80 USD |
Fair Price DCF | 9.79 USD |
HLN Dividends
Dividend Yield 12m | 1.66% |
Yield on Cost 5y | 2.34% |
Annual Growth 5y | 22.87% |
Payout Consistency | 100.0% |
Payout Ratio | 2.3% |
HLN Growth Ratios
Growth Correlation 3m | 83.4% |
Growth Correlation 12m | 59.6% |
Growth Correlation 5y | 90.1% |
CAGR 5y | 13.84% |
CAGR/Max DD 5y | 0.55 |
Sharpe Ratio 12m | 1.57 |
Alpha | 21.97 |
Beta | 0.218 |
Volatility | 23.92% |
Current Volume | 13128.4k |
Average Volume 20d | 15241k |
As of June 19, 2025, the stock is trading at USD 10.50 with a total of 13,128,362 shares traded.
Over the past week, the price has changed by -3.58%, over one month by -3.49%, over three months by +3.01% and over the past year by +27.57%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Haleon (NYSE:HLN) is currently (June 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 53.45 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLN is around 10.80 USD . This means that HLN is currently overvalued and has a potential downside of 2.86%.
Haleon has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy HLN.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- Strong Sell: 0
According to our own proprietary Forecast Model, HLN Haleon will be worth about 11.7 in June 2026. The stock is currently trading at 10.50. This means that the stock has a potential upside of +11.05%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 11.6 | 10.2% |
Analysts Target Price | 11.6 | 10.2% |
ValueRay Target Price | 11.7 | 11% |